The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-05 and is reviewed periodically as new material appears.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
=== Phylogeny === In molecular phylogenetics analysis, Parmotrema perlatum has a sister relationship with Parmotrema crinitum. These two species form a clade that itself is sister to a clade with P. austrosinense and P. tinctorum. In a comprehensive phylogenetic analysis by Stelate and colleagues (2022), P. perlatum and P crinitum were found to form a well-supported monophyletic group using internal transcribed spacer sequences and several analytical methods. This study highlights the complexity of species boundaries within the genus and the need for further research incorporating additional molecular markers to confirm these findings.
== Pharmacology == Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria. In individuals with paroxysmal nocturnal hemoglobinuria, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular (within the liver or spleen) hemolysis. By binding to and inhibiting C3, pegcetacoplan helps regulate complement activation, thereby reducing red blood cell destruction, anemia, blood clot formation, and improving bone marrow function. This targeted mechanism of action makes pegcetacoplan the first-in-class medication for the treatment of paroxysmal nocturnal hemoglobinuria, offering a promising therapeutic approach to address the underlying complement dysregulation in this condition.
US citizen Nicholas Rossi, wanted in Utah on rape charges, loses his appeal against extradition from the UK. The Scottish Government confirms it will delay plans to set up a National Care Service by three years, moving it back from 2026 to 2029. 15 December – The Met Office issues an amber weather alert ahead of an expected month's worth of rain on 17 December affecting the Highlands and northern Argyll. 17 December – The UK's first spaceport for vertical rocket launches is granted planning approval by the Civil Aviation Authority. Full orbital launches from the site, on the remote Scottish island of Unst, are expected to commence from 2025. 19 December – Finance Secretary Shona Robison presents the Scottish Government's budget for 2024–25. Measures announced include a new 45% tax rate for people earning between £75,000 and £125,140, and a rise in the top rate of tax, paid by those earning over £125,000, from 47% to 48%. The £43,663 tax threshold is also frozen for the year. 20 December – The Scottish Government confirms it will abandon its legal challenge against the UK government's veto of the Gender Recognition Reform (Scotland) Bill. Transport Secretary Mairi McAllan confirms plans to make the A9 a dual carriageway between Inverness and Perth will be delayed from 2025 to 2035; she also tells MSPs the original cost of the project has risen from £3bn to £3.7bn. Jo Farrell, the Chief Constable of Police Scotland, announces that the force will begin rolling out the use of body cameras from summer 2024.
== Theory == The use of micelles in high performance liquid chromatography was first introduced by Armstrong and Henry in 1980. The technique is used mainly to enhance retention and selectivity of various solutes that would otherwise be inseparable or poorly resolved. Micellar liquid chromatography (MLC) has been used in a variety of applications including separation of mixtures of charged and neutral solutes, direct injection of serum and other physiological fluids, analysis of pharmaceutical compounds, separation of enantiomers, analysis of inorganic organometallics, and a host of others. One of the main drawbacks of the technique is the reduced efficiency that is caused by the micelles. Despite the sometimes poor efficiency, MLC is a better choice than ion-exchange LC or ion-pairing LC for separation of charged molecules and mixtures of charged and neutral species. Some of the aspects which will be discussed are the theoretical aspects of MLC, the use of models in predicting retentive characteristics of MLC, the effect of micelles on efficiency and selectivity, and general applications of MLC. Reverse phase high-performance liquid chromatography (RP-HPLC) involves a non-polar stationary phase, often a hydrocarbon chain, and a polar mobile or liquid phase. The mobile phase generally consists of an aqueous portion with an organic addition, such as methanol or acetonitrile. When a solution of analytes is injected into the system, the components begin to partition out of the mobile phase and interact with the stationary phase.
=== Optimal solution === The optimal "threading" of a protein sequence onto a known structure and the production of an optimal multiple sequence alignment have been shown to be NP-complete. However, this does not imply that the structural alignment problem is NP-complete. Strictly speaking, an optimal solution to the protein structure alignment problem is only known for certain protein structure similarity measures, such as the measures used in protein structure prediction experiments, GDT_TS and MaxSub. These measures can be rigorously optimized using an algorithm capable of maximizing the number of atoms in two proteins that can be superimposed under a predefined distance cutoff. Unfortunately, the algorithm for optimal solution is not practical, since its running time depends not only on the lengths but also on the intrinsic geometry of input proteins.
Sources: en.wikipedia.org
Gas chromatography–mass spectrometry (GC–MS) is an analytical method that combines the features of gas-chromatography and mass spectrometry to identify different substances within a test sample. Applications of GC–MS include drug detection, fire investigation, environmental analysis, explosives investigation, food and flavor analysis, and identification of unknown samples, including that of material samples obtained from planet Mars during probe missions as early as the 1970s. GC–MS can also be used in airport security to detect substances in luggage or on human beings. Additionally, it can identify trace elements in materials that were previously thought to have disintegrated beyond identification. Like liquid chromatography–mass spectrometry, it allows analysis and detection even of tiny amounts of a substance. GC–MS has been regarded as a "gold standard" for forensic substance identification because it is used to perform a 100% specific test, which positively identifies the presence of a particular substance. A nonspecific test merely indicates that any of several in a category of substances is present. Although a nonspecific test could statistically suggest the identity of the substance, this could lead to false positive identification. However, the high temperatures (300°C) used in the GC–MS injection port (and oven) can result in thermal degradation of injected molecules, thus resulting in the measurement of degradation products instead of the actual molecule(s) of interest.
Asparagopsis requires very little processing. It is harvested from a seaweed farm then uses freeze drying or controlled drying to preserve as much bioactivity as possible. This can then be packaged and transported as required. Alternatively, it can be steeped in an edible oil, such as canola. Homogeneity of seaweed biomass within the feed must be maintained to ensure uniform intake for consistent effect. Asparagopsis is either one of two species: Asparagopsis taxiformis or Asparagopsis armata. Both species have very similar biochemistry and thus negligible difference in performance as an additive. The main distinction between either species is the conditions that each flourishes in. A. taxiformis thrives in tropical and subtropical climates and can be found in Australian coastal waters, predominantly in northern Queensland and Western Australia. A. armata thrives in temperate climates and is found naturally in the Mediterranean Sea and Tasman Sea.
Obesity: Across different cultures and ancestries, between 30% and 80% of women with PMOS are overweight or obese. There is marked weight gain between adolescence and adulthood, compared to those without PMOS. Dyslipidemia: disorders of fat (lipid) metabolism such as cholesterol and triglycerides: in PMOS, levels of low-density lipoprotein cholesterol are often high, while high-density cholesterol levels are low. Metabolic dysfunction–associated steatotic liver disease (MASLD; a chronic liver disease), particularly if androgen levels are high High blood pressure Metabolic syndrome, which occurs in about 40% of women with PMOS Cardiovascular disease: women with PMOS have about a two-fold increased risk of strokes and coronary heart disease compared to women without PMOS who have similar BMI. PMOS increases the risk of pregnancy complications, such as gestational diabetes, high blood pressure, low blood sugar levels, and pre-eclampsia. Miscarriages are more likely, and when a baby is delivered, they are more likely to require admission to the neonatal intensive care unit. PMOS is associated with mental health-related conditions including depression, anxiety, bipolar disorder, and obsessive–compulsive disorder. Those with PMOS often report reduced quality of life due to excess body weight, and to a lesser extent due to hirsutism, infertility and menstrual cycles. In regions where infertility or hirsutism are stigmatised, the impact on mental health is more severe. Body image can be negatively affected and PMOS increases the risk of eating disorders, such as binge eating.
=== Canada === During his visit to North America in August 1941, Howard Florey approached the Connaught Laboratories at the University of Toronto, where he met with the director, R. D. Defries, and Ronald Hare. Florey was rebuffed; Defries argued that the laboratories did not have the space, and he expressed his belief that constructing facilities to culture penicillin would be a waste as it would soon be synthesised. The results of clinical trials caused a change of heart, and in August 1943 the Canadian government asked the Connaught Laboratories to initiate mass production of penicillin. The Spadina Building was purchased by the University of Toronto for the purpose, and refurbished at a cost of Canadian $1.2 million (equivalent to Canadian $22 million in 2025), split equally between the university and the government. Penicillin was initially cultured in 200,000 bottles occupying 740 square metres (8,000 sq ft) of air-conditioned laboratory space. Production was switched to the deep submergence method in November 1945.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.